Literature DB >> 17690698

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.

M Bocchia, M Ippoliti, A Gozzetti, E Abruzzese, S Calabrese, M Amabile, M T Pirrotta, R Crupi, D Tozzuoli, M M Trawinska, M Defina, G Martinelli, F Lauria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17690698     DOI： 10.1038/sj.leu.2404893

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  Molecular resistance: an early indicator for treatment change?

Authors:  Carmen Fava; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-01-28

Review 2.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

3.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

Authors:  Jean-Claude Chomel; Marie-Laure Bonnet; Nathalie Sorel; Angelina Bertrand; Marie-Claude Meunier; Serge Fichelson; Michael Melkus; Annelise Bennaceur-Griscelli; François Guilhot; Ali G Turhan
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

Review 4.  Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.

Authors:  Igor Valentim Barreto; Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Germison Silva Lopes; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Lucas Eduardo Botelho de Souza; Rommel Mário Rodriguez Burbano; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

5.  Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Authors:  Jean-Claude Chomel; Ali G Turhan
Journal:  Oncotarget       Date:  2011-09

6.  Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.

Authors:  Jin Lou; Junjie Huang; Zitong Wang; Bingbing Wen; Chuanqing Tu; Wangxiang Huang; Zhimin Zhai; Xin Du
Journal:  Patient Prefer Adherence       Date:  2018-06-15       Impact factor: 2.711

7.  Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Authors:  Monica Bocchia; Anna Sicuranza; Elisabetta Abruzzese; Alessandra Iurlo; Santina Sirianni; Antonella Gozzini; Sara Galimberti; Lara Aprile; Bruno Martino; Patrizia Pregno; Federica Sorà; Giulia Alunni; Carmen Fava; Fausto Castagnetti; Luca Puccetti; Massimo Breccia; Daniele Cattaneo; Marzia Defina; Olga Mulas; Claudia Baratè; Giovanni Caocci; Simona Sica; Alessandro Gozzetti; Luigiana Luciano; Monica Crugnola; Mario Annunziata; Mario Tiribelli; Paola Pacelli; Ilaria Ferrigno; Emilio Usala; Nicola Sgherza; Gianantonio Rosti; Alberto Bosi; Donatella Raspadori
Journal:  Front Oncol       Date:  2018-05-30       Impact factor: 6.244

8.  Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.

Authors:  Ester Pungolino; Mariella D'adda; Gabriella De Canal; Alessandra Trojani; Alessandra Perego; Chiara Elena; Francesca Lunghi; Mauro Turrini; Lorenza Borin; Alessandra Iurlo; Maria Luisa Latargia; Maria Cristina Carraro; Francesco Spina; Salvatore Artale; Michela Anghilieri; Alfredo Molteni; Marianna Caramella; Giacomo Baruzzo; Michele Nichelatti; Barbara Di Camillo; Roberto Cairoli
Journal:  Eur J Haematol       Date:  2021-07-06       Impact factor: 3.674
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.